Even though GM-CSF therapy for cryptococcosis has not yet been evaluated, there is logic to suggest that it might be a useful therapeutic since those who have autoantibodies against GM-CSF are more likely to contract Cryptococcus infection; but even so, an effective dosage must be established to counteract the neutralizing autoantibodies (196). Here, CSF2 is linked to cryptococcosis.